Higher susceptibility to 6 Hz corneal kindling and lower responsiveness to antiseizure drugs in mouse models of Alzheimer's disease.
Autor: | Vande Vyver M; Department of Pharmaceutical Chemistry, Drug Analysis and Drug Information, Research Group Experimental Pharmacology, Center for Neurosciences, Vrije Universiteit Brussel, Brussels, Belgium.; Department of Neurology, Universitair Ziekenhuis Brussel, Jette, Belgium.; Reference Center for Biological Markers of Dementia (BIODEM), Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.; Neuroprotection and Neuromodulation (NEUR), Center for Neurosciences, Vrije Universiteit Brussel, Brussels, Belgium., Barker-Haliski M; Department of Pharmacy, University of Washington, Seattle, Washington, USA., Aourz N; Department of Pharmaceutical Chemistry, Drug Analysis and Drug Information, Research Group Experimental Pharmacology, Center for Neurosciences, Vrije Universiteit Brussel, Brussels, Belgium., Nagels G; Department of Neurology, Universitair Ziekenhuis Brussel, Jette, Belgium.; Department of AI Supported Modelling in Clinical Sciences (AIMS), Vrije Universiteit Brussel, Brussels, Belgium., Bjerke M; Neuroprotection and Neuromodulation (NEUR), Center for Neurosciences, Vrije Universiteit Brussel, Brussels, Belgium.; Department of Neurochemistry, Universitair Ziekenhuis Brussel, Brussels, Belgium., Engelborghs S; Department of Neurology, Universitair Ziekenhuis Brussel, Jette, Belgium.; Reference Center for Biological Markers of Dementia (BIODEM), Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.; Neuroprotection and Neuromodulation (NEUR), Center for Neurosciences, Vrije Universiteit Brussel, Brussels, Belgium., De Bundel D; Department of Pharmaceutical Chemistry, Drug Analysis and Drug Information, Research Group Experimental Pharmacology, Center for Neurosciences, Vrije Universiteit Brussel, Brussels, Belgium., Smolders I; Department of Pharmaceutical Chemistry, Drug Analysis and Drug Information, Research Group Experimental Pharmacology, Center for Neurosciences, Vrije Universiteit Brussel, Brussels, Belgium. |
---|---|
Jazyk: | angličtina |
Zdroj: | Epilepsia [Epilepsia] 2022 Oct; Vol. 63 (10), pp. 2703-2715. Date of Electronic Publication: 2022 Aug 02. |
DOI: | 10.1111/epi.17355 |
Abstrakt: | Objective: Epileptic spikes and seizures seem present early in the disease process of Alzheimer's disease (AD). However, it is unclear how soluble and insoluble amyloid beta (Aβ) and tau proteins affect seizure development in vivo. We aim to contribute to this field by assessing the vulnerability to 6 Hz corneal kindling of young female mice from two well-characterized transgenic AD models and by testing their responsiveness to selected antiseizure drugs (ASDs). Methods: We used 7-week-old triple transgenic (3xTg) mice that have both amyloid and tau mutations, and amyloid precursor protein Swedish/presenillin 1 dE9 (APP/PS1) mice, bearing only amyloid-related mutations. We assessed the absence of plaques via immunohistochemistry and analyzed the concentrations of both soluble and insoluble forms of Aβ Results: No Aβ plaques were present in either genotype. Soluble Aβ Significance: Mutations increasing Aβ only or both Aβ and tau in the brain enhance susceptibility for seizures and kindling in mice. The effect of ASDs on seizures measured by the Racine scale is less pronounced in both investigated AD models and suggests that seizures of young AD mice are more difficult to treat. (© 2022 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.) |
Databáze: | MEDLINE |
Externí odkaz: |